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346Objective: To investigate the efficacy of bosentan in patients with single-ventricle physiology who were unable
to undergo right-sided heart bypass surgery because of high pulmonary vascular resistance and pulmonary artery
pressure.
Methods: Eight patients with single-ventricle physiology (2 male and 6 female; aged 7 months to 5 years, median 1
year) were enrolled. Prior surgical interventions included pulmonary artery banding in 4 patients, Blalock–Taussig
shunt operation in 2 patients, and bidirectional Glenn operation in 5 patients. Right-sided heart bypass surgery was
contraindicated for all patients because of high pulmonary vascular resistance and pulmonary artery pressure.
Results: Bosentan therapy successfully reduced pulmonary artery pressure and pulmonary vascular resistance in
all patients. Mean pulmonary artery pressure at baseline and after bosentan therapy was 21.1  7.2 mm Hg and
11.9  4.1 mm Hg, respectively (P< .01). Mean pulmonary vascular resistance index at baseline and after bo-
sentan therapy was 5.7  3.3 U/m2 and 1.3  0.4 U/m2, respectively (P< .01). Mean pulmonary vascular resis-
tance/systemic vascular resistance at baseline and after bosentan therapy was 0.25  0.11 and 0.07  0.03,
respectively (P<.01). All patients had improved clinical symptoms and underwent successful Fontan operations.
Conclusion: Bosentan induces mid-term clinical and hemodynamic improvement in patients with single-
ventricle physiology and elevated pulmonary vascular resistance and pulmonary artery pressure. Bosentan
therapy may increase the surgical options and improve outcomes in candidates for right-sided heart bypass sur-
gery. (J Thorac Cardiovasc Surg 2010;140:346-51)In recent years, new treatment strategies have largely im-
proved the clinical status and life expectancy of patients
with pulmonary artery hypertension (PAH).1 Bosentan, an
oral dual endothelin (A and B) receptor antagonist, has
been shown to be effective in patients with idiopathic
PAH and PAH related to connective tissue disease, improv-
ing long-term quality of life.2-4 During the past few years,
small open-label studies have suggested that bosentan is
safe and well tolerated in adults with congenital heart disease
(CHD) and that it improves functional status and exercise ca-
pacity.5,6 These pilot studies triggered the first large
randomized controlled trial of bosentan in patients with
Eisenmenger syndrome, showing a beneficial short-term ef-
fect of bosentan on exercise capacity and hemodynamics
without compromising systemic oxygen saturation.7
Nonetheless, there are few reports so far on the effect of
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The Journal of Thoracic and Cardiovascular Surgpulmonary vascular resistance (PVR) in patients with
single-ventricle (SV) physiology. Apostolopoulou and col-
leagues8 reported that bosentan induced clinical, exercise,
and hemodynamic improvement in a 14-year-old patient
with failing Fontan circulation, high PAP, and plastic bron-
chitis.8 Votava-Smith and colleagues9 used bosentan to treat
PVR in a 10-year-old patient with SV physiology and a bidi-
rectional Glenn shunt.
Thus, we hypothesized that endothelin may play an
important role in maintaining vasoconstriction in SV physi-
ology before and after right-sided heart bypass surgery, and
that the endothelin receptor antagonist bosentan may induce
hemodynamic improvement in patients with SV physiology
with decreased PVR and PAP, which would increase the
surgical options. This study examined the efficacy of bosen-
tan in patients with SV physiology who were unable to un-
dergo right-sided heart bypass surgery because of high PVR
and PAP.MATERIALS AND METHODS
Patients
A total of 28 patients with SV physiology underwent cardiac catheteriza-
tion to evaluate the indication for Fontan operation at the University
Hospital of Toyama University between January 2006 and April 2009.
Among them, 8 patients were unable to undergo right-sided heart bypass
surgery because of high PVR (3 U/m2) and mean PAP (18 mm Hg).
The remaining 20 patients, who did not have high PVR (<3 U/m2) and
mean PAP (<18 mm Hg), underwent Fontan operation successfully and
were designated the non-PAH group.ery c August 2010
TABLE 1. New York University Pediatric Heart Failure Index Heart
failure severity determined from signs and symptoms, medical
regimen, and ventricular physiology
Score
Signs and symptoms
þ2 Abnormal ventricular function by echocardiogram or gallop
þ2 Dependent edema, pleural effusion, or ascites
þ2 Failure to thrive or cachexia
þ1 Marked cardiomegaly by x-ray or physical examination
þ1 Reported physical activity intolerance or prolonged feeding time
þ2 Poor perfusion by physical examination
þ1 Pulmonary edema by x-ray or auscultation
þ2 Resting sinus tachycardia
þ2 Retractions
þ1 Hepatomegaly
þ2 <4 cm below costal margin
þ1 >4 cm below costal margin
þ2 Observed tachypnea or dyspnea
Mild to moderate
Moderate to severe
Medications
þ1 Digoxin
þ1 Diuretics
þ2 Low to moderate dose
þ1 High-dose or>1 diuretic
þ1 ACE-I, other vasodilators, or ARB
þ2 b-blockers
þ2 Anticoagulants not related to prosthetic valves
Antiarrhythmic agents or implantable cardiac defibrillator
Physiology
þ2 Single ventricle
Abbreviations and Acronyms
CHD ¼ congenital heart disease
NYUPHFI ¼ New York University Pediatric
Heart Failure Index
PAH ¼ pulmonary artery hypertension
PAP ¼ pulmonary artery pressure
PVR ¼ pulmonary vascular resistance
SV ¼ single ventricle
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sity Pediatric Heart Failure Index (NYUPHFI).10 This score is derived by
the linear combination of scores based on symptoms, physical signs, and
medical regimen (Table 1). Healthy children without heart failure are ex-
pected to score low (<2 points).10 All enrolled patients had PAH related
to CHD with or without prior surgical repair and fixed elevated PVR that
precluded further surgical intervention.
Care was taken to exclude other causes of pulmonary hypertension,
such as pulmonary arterial hypoplasia, hypoventilation, and lung or liver
disease. Patients had no treatment regimen changes within the last month
before enrollment and during the study period, aside from the addition
of bosentan treatment. No patients were taking epoprostenol, glibencla-
mide, or cyclosporine, to avoid drug interactions, or calcium channel
blockers, because they were unresponsive to vasodilators. All patients
were clinically evaluated once every month by electrocardiography,
echocardiography, oxygen saturation measurement, and NYUPHFI score
assessment. Liver enzyme levels were measured every 2 months in patients
treated with bosentan.
The research ethics committee of the University Hospital of Toyama ap-
proved the study. Written informed consent was obtained from parents after
the purpose and procedures of the study were fully explained.
ACE-I, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Adding scores attributed to each individual criterion derives a total score. Scores can
range from 0 (no heart failure) to 30 (severe heart failure). Adapted from Connolly D,
Rutkowski M, Auslender M, Artman M. The New York University Pediatric Heart
Failure Index: a new method of quantifying chronic heart failure severity in children.
J Pediatr. 2001;138:644-8.Study Design
Patients started a twice daily oral bosentan regimen of 0.5 to 1 mg/kg per
dose. The dose of bosentan was increased 0.5 to 1mg/kg every 4 weeks until
reaching 3 mg/kg per dose.
All patients were evaluated before initiation and after bosentan treatment
regarding history and subjected to clinical examination to define
NYUPHFI, an unstructured interview including questions about perceived
well-being and exercise ability, and evaluations of maximal and submaxi-
mal exercise capacity. Complete hemodynamic studies were simulta-
neously performed before and after bosentan treatment. Drug safety was
evaluated bimonthly by monitoring adverse events, such as flushing and na-
sal congestion; laboratory tests, such as liver function tests and hemoglobin
concentration; electrocardiogram; vital signs; pulse oximetry recordings;
and discontinuations.
Cardiac catheterization was performed just before starting bosentan and
after bosentan therapy to select surgical options; this was performed under
local anesthesia with additional intravenous sodium thiopental. Similarly,
cardiac catheterization was performed in the non-PAH group to evaluate
the indication of the Fontan operation. Blood gas analysis showed normal
partial carbon dioxide acid base status during cardiac catheterization. Pul-
monary arterial, right atrial, and pulmonary capillary wedge pressures
and systemic pressures were recorded. Systemic and pulmonary arterial
and venous saturations were obtained to calculate cardiac outputs with
the Fick principle and table-derived oxygen consumption values.11 Oxygen
saturations obtained from pulmonary veins, when possible, or several pul-
monary capillary wedge positions were used to calculate pulmonary venous
oxygen content. For great artery level shunts, oxygen saturations from both
distal pulmonary arteries were used to calculate pulmonary arterial oxygenThe Journal of Thoracic and Cacontent. Calculation of systemic flow was adequate because oxygen satura-
tions were equal throughout the systemic circuit in all patients. The trans-
pulmonary pressure gradient was defined as the difference between mean
PAP and mean pulmonary capillary wedge or left atrial pressure. Pulmo-
nary and systemic vascular resistance indices were calculated with the
standard formula.12 Baseline catheterization studies included hyperoxia
or vasodilator challenge to define fixed elevated PVR. Brain natriuretic
peptide was quantified at the time of cardiac catheterization. All patients
underwent lung perfusion scintigraphy to assess the right-to-left shunt be-
fore bosentan therapy.13 We combined these data and analyzed pulmonary
hemodynamics.
Statistical Analysis
All results were expressed as mean  standard deviation. Paired t test
was used to test for significance of the same parameter within the same
group. If data did not follow a normal distribution, the paired t test was re-
placed by a Wilcoxon signed-rank test. When the data followed a normal
distribution determined by Shapiro–Wilks test, comparisons between 2
groups were performed using an unpaired Student t test or a Welch’s test
depending on equal or unequal variance. If the data did not follow a normal
distribution, then a Mann–Whitney U test was used. All P values were
2-tailed.rdiovascular Surgery c Volume 140, Number 2 347
TABLE 2. Baseline clinical and functional characteristics of patients
Patient Diagnosis Age Gender
Pulse
oximetry (%) Symptoms Medications NYUPHFI
1 Asplenia, SV, DORV,
CoA, TAPVR
9 mo F 84 Cyanosis Diuretics, warfarin, aspirin, beraprost 9
2 Asplenia, SV, MA,
DORV, TAPVR
8 mo F 71 DOE, cyanosis Diuretics, aspirin, beraprost 8
3 Asplenia, SV, DORV,
PS, TAPVR
1 y F 81 DOE, cyanosis Diuretics, warfarin,
aspirin, beraprost, ACE-I,
sildenafil
12
4 Asplenia, SV, CAVC,
DORV, PS, TAPVR
7 mo M 80 Cyanosis Diuretics, warfarin, beraprost,
aspirin, ACE-I
9
5 HLHS 10 mo F 74 Cyanosis Diuretics, warfarin,
aspirin, beraprost, digoxin, ACE-I,
b-blocker
11
6 HLHS 2 y M 75 Cyanosis Diuretics, warfarin,
aspirin, beraprost, digoxin
11
7 HLHS 5 y F 86 DOE, cyanosis Diuretics, warfarin,
aspirin, beraprost, b-blocker,
pimobendan
15
8 SV, DORV, d-MGA 1 y F 72 Cyanosis Diuretics, warfarin,
aspirin, beraprost, ACE-I, ARB
9
NYUPHFI, New York University Pediatric Heart Failure Index; SV, single ventricle; DORV, double outlet right ventricle; CoA, coarctation of aorta; TAPVR, total anomalous of
pulmonary venous return;MA,mitral atresia; PS, pulmonary stenosis;CAVC, complete atrioventricular canal;HLHS, hypoplastic left heart syndrome; d-MGA, d-malposition of the
great arteries; DOE, dyspnea on exertion; ACE-I, angiotensin-converting enzyme–inhibitor; ARB, angiotensin receptor blocker.
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Patient Clinical Characteristics
All 8 patients started bosentan therapy between January
2006 and April 2009, with follow-up through September
2009. Tables 2 and 3 shows the clinical characteristics of
the 8 patients with PAH related to CHD, including
descriptions of the procedures/surgeries performed. All
patients had PAH associated with relative overcirculation
to hypoplastic pulmonary vasculature. The 8 patients had
higher mean PAP (P< .01), higher PVR (P< .01), and
smaller pulmonary artery index (P< .01) compared with
the non-PAH group (Table 4). All patients were significantly
symptomatic (NYUPHFI score 12.5  2.3) and cyanotic
with pulse oximetry (mean 77.9%  5.6%). All patients
had taken beraprost before bosentan therapy (median 5.5
months, 1–65 months), but clinical and hemodynamic im-
provement was not observed because of relative overcircula-
tion to a diminished pulmonary vasculature.Treatment Effect
Clinical and hemodynamic evaluation was performed at
baseline and after 5 to 17 months (mean 8 months). Results
at baseline and after bosentan therapy were as follows: mean
main PAP: 21.1  7.2 mm Hg and 11.9  4.1 mm Hg, re-
spectively (P ¼ .0014); PVR: 5.7  3.3 U/m2 and 1.3 
0.4 U/m2, respectively (P ¼ .0035); PVR/systemic vascular
resistance: 0.25  0.11 and 0.07  0.03, respectively
(P ¼ .0009) (Table 4). However, cardiac index, Qp/Qs,
pulse oximetry, and hemoglobin were not significantly348 The Journal of Thoracic and Cardiovascular Surgchanged, but brain natriuretic peptide and NYUPHFI
improved significantly. After bosentan therapy, 3 patients
underwent bidirectional Glenn surgery and all 8 patients suc-
cessfully underwent Fontan surgery (Table 3).
After the Fontan operation, all patients continued bosentan
therapy. However, 2 patients (numbers 1 and 2) were admit-
ted to the hospital once because of protein-losing enteropathy,
but they recovered completely with heparin therapy (Tables 2
and 3). The remaining 6 patients had no complications,
including protein-losing enteropathy, plastic bronchitis, and
liver dysfunction. The average NYUPHFI score in the 8 pa-
tients improved to 6.0  0.5 after Fontan surgery.Safety and Tolerability
All patients maintained adequate serum bosentan concen-
trations during therapy (Table 5). As we administered initial
doses of bosentan adjusting for patients’ body weight, ta-
chypnea and chest discomfort did not occur in any of the pa-
tients. Abnormal hepatic function, interference with the
international normalized ratio, and other adverse events
were not observed in this study.DISCUSSION
We show that bosentan therapy reduces PAP and PVR in
patients with SV physiology who are unable to undergo
right-sided heart bypass surgery because of high PVR and
PAP. With the support of bosentan therapy, the bidirectional
Glenn procedure was performed in 3 cases, and the Fontan
operation was completed successfully in all 8 cases.ery c August 2010
TABLE 3. Palliative surgery before bosentan and latest operations after bosentan
Patients Diagnosis Age Prior operation
Starting age of
bosentan Age
After bosentan
therapy
1 Asplenia, SV, DORV, 2 d CoA repair, PAB 9 mo 1 y BDG
CoA, TAPVR 23 d re-PAB 2 y Fontan
7 mo re-re-PAB
8 mo TAPVR repair
2 Asplenia, SV, MA, 1 mo PAB 8 mo 11 mo BDG
DORV, TAPVR 2 mo TAPVR repair 2 y Fontan
3 Asplenia, SV, DORV, 19d TAPVR repair 1 y 2 y BDG
PS, TAPVR 1 y Right modified BT shunt 3 y Fontan
4 Asplenia, SV, CAVC, 2 mo CAVVP 7 mo 2 y Fontan
DORV, PS, TAPVR 1 y BDG
5 HLHS 2 d PTAV 10 mo 2 y Fontan
15 d Bilateral PAB
4 mo Norwood, MVP
8 mo Right BDG, intrapulmonary artery
septation*
6 HLHS 7 d Norwood 2 y 2 y Fontan
7 mo BDG
7 HLHS 8 d Norwood 5 y 6 y Fontan, CRTy
8 mo Left modified BT shunt
1 y Right modified BT shunt
2 y BDG
2 y PMI
8 SV, DORV, d-MGA 1 mo PAB 1 y 2 y DKS, Fontan
7 mo BDG, ASD enlargement, re-PAB
SV, Single ventricle; DORV, double outlet right ventricle; CoA, coarctation of aorta; TAPVR, total anomalous of pulmonary venous return; MA, mitral atresia; PS, pulmonary ste-
nosis; PAB, pulmonary artery banding; CAVC, complete atrioventricular canal; HLHS, hypoplastic left heart syndrome; d-MGA, d-malposition of the great arteries; CAVVP, com-
mon atrial ventricular valvular plasty; BDG, bidirectional Glenn; PTAV, percutaneous transluminal balloon aortic valvuloplasty;MVP,mitral valvular plasty; BT, Blalock–Taussig;
PMI, pacemaker implantation; ASD, atrial septal defect; CRT, cardiac resynchronization therapy; DKS, Damus–Kaye–Stansel. *Patient 4 had intrapulmonary artery septation and
right BDG caused by left pulmonary artery stenosis. The flow of the superior vena cava was connected to the right pulmonary artery, and the flow of the left pulmonary artery was
supplied by the right ventricular pulmonary artery shunt.24 yPatient 7 had dysrhythmia and heart failure caused by ventricular dyssynchrony before the Fontan operation. Cardiac
resynchronization therapy was performed with Fontan operation.
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than 3 or 4 Woods units are known risk factors for death or
failure of anastomosis in patients with bidirectional Glenn
shunts.14,15TABLE 4. Hemodynamic parameters before and after bosentan treatmen
Non-PAH group
(n ¼ 20)
Before bosentan
treatment (n ¼ 8)
Body weight (kg) 7.3  1.2 7.1  1.8
Body surface area (m2) 0.36  0.05 0.34  0.09
Main mean PAP (mm Hg) 12.4  4.1 21.1  7.2
PVR (U/m2) 1.50  0.57 5.72  3.34
PVR/SVR 0.08  0.02 0.25  0.11
PA index 412  154.0 237  119.2
Cardiac index (L/min/m2) 3.36  0.80 3.59  1.12
Qp/Qs 1.47  0.60 0.93  0.44
Hb (g/dL) 15.6  1.3 15.3  1.4
Pulse oxymetry (%) 79.6  5.7 77.9  5.6
BNP (pg/mL) 123.4  253.1 221.5  189.6
NYUPHFI score 5.6  1.6 10.5  2.3
PAH, Pulmonary artery hypertension; PAP, pulmonary artery pressure; PVR, pulmonary v
monary blood flow; Qs, systemic blood flow; Hb, hemoglobin; BNP, brain natriuretic
mean  standard deviation. P value is derived from comparison of before and after bosent
The Journal of Thoracic and CaEndothelin has been implicated in the pathogenesis of
pulmonary hypertension secondary to CHD. Endothelin me-
diates vasoconstriction and induces vascular smooth muscle
cell contraction, proliferation, and inflammation. Increasedt
After bosentan
treatment (n ¼ 8) Percentage change (%) P value
9.1  2.1 þ27.9 .0088
0.45  0.09 þ32.4 .0171
11.9  4.1 43.8 .0014
1.30  0.43 77.3 .0035
0.07  0.03 72.0 .0009
242.1  81.6 þ2.0 .4180
3.16  1.05 12.0 .1962
1.06  0.42 þ14.0 .2286
15.5  2.6 þ1.0 .4266
83.5  4.8 þ7.2 .0164
65.4  70.9 70.5 .0367
8.0  2.4 23.8 .0026
ascular resistance; SVR, systemic vascular resistance; PA, pulmonary artery; Qp, pul-
peptide; NYUPHFI, New York University Pediatric Heart Failure Index. Data are
an treatment.
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TABLE 5. Dosage and side effects of bosentan
Patient Duration
Dosage
(mg/kg/d)
Concentration
(trough) (ng/mL)
Concentration
(peak) (ng/mL) Adverse effect
1 1 y 1 27.6 78.6 None
2 1 y 2 27.5 76.6 None
3 1 y 2 102.1 522.8 None
4 10 mo 2 17.3 136.1 None
5 8 mo 3 55.8 704.0 None
6 1 y 2 52.3 365.8 None
7 7 mo 3 187.2 220.6 None
8 6 mo 2 147.3 399.4 None
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biopsies of patients with CHD and PAH.16,17 Elevated
PAP and excessive pulmonary flow have been associated
with elevated endothelin-1 levels in experimental models
and in patients with CHD.18,19
The use of bosentan in pediatric patients was evaluated in
a prospective, open-label pharmacokinetic study in 19 chil-
dren with idiopathic PAH or PAH related to CHD.20 Bosen-
tan treatment for 12 weeks resulted in hemodynamic
improvement and formed the basis of the current dosing
schedule for the drug in pediatric patients.20 In a retrospec-
tive study of 86 pediatric patients primarily with idiopathic
PAH or PAH related to CHD, bosentan improved or main-
tained World Health Organization functional class and
improved hemodynamics.21 Kaplan–Meier estimates of sur-
vival at 1 and 2 years were 98% and 91%, respectively. In
another retrospective study of 40 pediatric patients, bosentan
helped stabilize children with idiopathic PAH, but intrave-
nous epoprostenol was also needed by 60%. Children
with PAH related to other conditions improved.22
It has been reported that plasma endothelin-1 is elevated
and adrenomedullin is decreased after Fontan operations,
and an imbalance between endothelin-1 and adrenomedullin
might induce vasoconstriction.23 There was a positive corre-
lation between endothelin-1 levels and PVR.23 Although we
did not examine the serum level of endothelin, the bosentan
doses used in this study were efficacious and of benefit to pa-
tients with Fontan circulation.
These results suggest that bosentan may induce hemody-
namic improvement in patients with SV physiology with
decreased PVR and PAP, thus increasing the surgical op-
tions. Further, endothelin may play an important role in
maintaining vasoconstriction in SV physiology before and
after right-sided heart bypass surgery.Study Limitations
Within a few months of starting bosentan therapy, some
of our patients had surgical procedures that may have had
slowly developing favorable effects on PVR. However,
catheterization data before starting bosentan showed fixed350 The Journal of Thoracic and Cardiovascular Surgelevated PVR even on hyperoxia or vasodilator challenge,
so favorable effects on PVR cannot be explained only by
delayed effect of before surgical procedures. Our study
was limited to a small number of patients. Larger, placebo-
controlled studies with long-term administration of bosentan
are needed to assess the optimal doses and possible thera-
peutic role of bosentan in this patient population.CONCLUSIONS
Bosentan therapy reduced PAP and PVR and improved
clinical symptoms and exercise tolerance in all cases. Bosen-
tan induced mid-term clinical and hemodynamic improve-
ment in patients with SV physiology with increased PVR.
Bosentan therapy may increase the surgical options and im-
prove the outcome in Fontan candidates with increased PVR
secondary to diminished pulmonary vasculature and relative
pulmonary overcirculation.
The authors thank Neil Bowles, Hironori Matsuhisa, Chisato
Akita, Keiichirou Uese, Watanabe-Ozawa Sayaka, Keijirou Ibuki,
and Kazuyoshi Saito for assistance.References
1. Galie` N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al.
Guidelines on diagnosis and treatment of PAH. The Task Force on Diagnosis
and Treatment of Pulmonary Arterial Hypertension of the European Society of
Cardiology. Eur Heart J. 2004;25:2243-78.
2. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan
therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
3. Galie` N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of
clinical trials and evidence-based treatment algorithm in pulmonary arterial hy-
pertension. J Am Coll Cardiol. 2004;43:81-8.
4. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al.
Effects of the dual endothelin receptor antagonist bosentan in patients with pul-
monary hypertension: a randomized placebo–controlled study. Lancet. 2001;
358:1119-23.
5. Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, et al. Safety and
tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol.
2005;98:147-51.
6. Schulze-Neick I, Gilbert N, Ewert R, Witt C, Gruenig E, Enke B, et al. Adult
patients with congenital heart disease and pulmonary hypertension: first open
prospective multicenter study of bosentan therapy. Am Heart J. 2005;150:
716.
7. Galie` N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al.
Bosentan therapy in patients with Eisenmenger syndrome. A multicenter, dou-
ble–blind, randomized, placebo controlled study. Circulation. 2006;114:48-54.ery c August 2010
Hirono et al Congenital Heart Disease
C
H
D8. Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exer-
cise and hemodynamic improvement in a pre-transplant patient with plastic
bronchitis after Fontan operation. J Heart Lung Transplant. 2005;24:1174-6.
9. Votava-Smith JK, Perens GS, Alejos JC. Bosentan for increased pulmonary vas-
cular resistance in a patient with single ventricle physiology and a bidirectional
Glenn shunt. Pediatr Cardiol. 2007;28:314-6.
10. Connolly D, Rutkowski M, Auslender M, Artman M. The New York University
Pediatric Heart Failure Index: a new method of quantifying chronic heart failure
severity in children. J Pediatr. 2001;138:644-8.
11. Bridges ND, O’Lauhlin MP, Mullins CE, Freed MD. In: Allen HD, Gutgesell HP,
Clark EB, Driscoll DJ, eds. Moss and Adams Heart Disease in Infants, Children,
and Adolescents. Cardiac catheterization, angiography, and intervention, Volume
1. Baltimore: Williams & Wilkins; 2001:276-324.
12. Grossman W. Clinical measurement of vascular resistance and assessment of va-
sodilator drugs. In: Grossman W, ed. Cardiac Catheterization and Angiography.
Philadelphia: Lea and Febiger; 1991:143-51.
13. Cloutier A, Ash JM, Smallhorn JF, Williams WG, Trusler GA, Rowe RD, et al.
Abnormal distribution of pulmonary blood flow after the Glenn shunt or Fontan
procedure: risk of development of arteriovenous fistulae. Circulation. 1985;72:
471-9.
14. Alejos JC, Williams RG, Jarmakani JM, Galindo AJ, Isabel-Jones JB,
Drinkwater D, et al. Factors influencing survival in patients undergoing the bidi-
rectional Glenn anastomosis. Am J Cardiol. 1995;75:1048-50.
15. Pridjian AK, Mendelsohn AM, Lupinetti FM, Beekman RH 3rd, Dick M 2nd,
Serwer G, et al. Usefulness of the bidirectional Glenn procedure as a staged recon-
struction for the functional single ventricle. Am J Cardiol. 1993;71:959-62.
16. Lutz J, Gorenflo M, Habighorst M, Vogel M, Lange PE, Hocher B. Endothe-
lin-1- and endothelin-receptors in lung biopsies of patients with pulmonaryThe Journal of Thoracic and Cahypertension due to congenital heart disease. Clin Chem Lab Med. 1999;37:
423-8.
17. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, et al.
Plasma endothelin concentrations in patients with pulmonary hypertension
associated with congenital heart defects. Evidence for increased production of
endothelin in pulmonary circulation. Circulation. 1991;84:2280-5.
18. Fratz S, Geiger R, Kresse H, Roemer G, Hennig M, Sebening W, et al. Pulmonary
blood pressure, not flow, is associated with net endothelin-1 production in the
lungs of patients with congenital heart disease and normal pulmonary vascular re-
sistance. J Thorac Cardiovasc Surg. 2003;126:1724-9.
19. Vincent JA, Ross RD, Kassab J, Hsu JM, Pinsky WW. Relation of elevated
plasma endothelin in congenital heart disease to increased pulmonary blood
blow. Am J Cardiol. 1993;71:1204-7.
20. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmaco-
kinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary ar-
terial hypertension. Clin Pharmacol Ther. 2003;73:372-82.
21. Rosenzweig EB, Ivy DD,Widlitz A, Doran A, Claussen LR, Yung D, et al. Effects
of long–term bosentan in children with pulmonary arterial hypertension. J Am
Coll Cardiol. 2005;46:697-704.
22. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children
with pulmonary hypertension. Heart. 2006;92:664-70.
23. Hiramatsu T, Imai Y, Takanashi Y, Seo K, Terada M, Aoki M, et al. Time course
of endothelin-1 and adrenomedullin after the Fontan procedure. Ann Thorac Surg.
1999;68:169-72.
24. Sakamoto K, Ikai A, Fujimoto Y, Ota N. Novel surgical approach ‘intrapulmo-
nary-artery septation’ for Fontan candidates with unilateral pulmonary arterial hy-
poplasia or pulmonary venous obstruction. Interact Cardiovasc Thorac Surg.
2007;6:150-4.rdiovascular Surgery c Volume 140, Number 2 351
